Purpose: Osteoarthritis (OA) is characterized by joint degeneration, leading to a progressive loss of articular cartilage in response to mechanical and biochemical factors. However, OA is a complex disease not limited to cartilage degeneration. Indeed, several sets of in vitro and in vivo experiments suggest that subchondral bone remodeling could initiate and/or contribute to cartilage loss in OA through a bone/ cartilage interplay. The aim of this study was to demonstrate the ability of soluble mediators released by loaded osteoblasts to shift the articular chondrocyte phenotype from a resting to a pro-degradative phenotype through a novel and unique bone/cartilage communication model. Methods: Thanks to a three dimensional (3D) culture model, murine calvaria osteoblasts were submitted to compression in Biopress Flexercell plates (1.7 MPa, 1Htz during 24h). Then, media from loaded or unloaded osteoblasts were used to treat primary mouse articular chondrocytes for 24h. Chondrocyte expression and secretion of matrix metalloproteinases (MMP-3 and -13), MMPs inhibitors (TIMP-1, -2 and -3) and extracellular matrix proteins (type II collagen, aggrecan) were analyzed by real time RT-PCR, ELISA and immunoblotting. Osteoblast conditioned media were then analyzed by iTRAQ (isobaric tags for relative and absolute quantification), a quantitative proteomic approach. Results: Media from compressed osteoblast (CM) strongly induced MMP-3 and -13 chondrocyte mRNA expression (Table) . Consistently, CM also significantly stimulated the releases of MMP-3 and -13 by chondrocytes (respectively 10.6AE0.75 fold, p<0.001, and 6.5AE2.1 fold, p<0.01 compared to control). In addition, CM enhances TIMP-1 expression whereas it strongly inhibited TIMP-2 and -3 expressions (Table) . Osteoblast conditioned media also affected cartilage matrix proteins expressions. Indeed, CM downregulated aggrecan and type II collagen mRNA levels (Table) . Effects of CM on cytosolic type II collagen protein amounts were confirmed by western blot (a decrease of 31AE9%, p<0.01). Finally, in order to identify osteoblast soluble mediators responsible for this chondrocyte phenotype, osteoblast conditioned media were analyzed by iTRAQÒ. This advanced and sophisticated new proteomic technique allowed identification of 105 proteins secreted by osteoblasts among which only 10% were modified in response to compression. Conclusions: These results support the hypothesis that soluble mediators released by bone cells submitted to a mechanical stress promote chondrocyte activation leading to the release of pro-degradative mediators. Analysis of these soluble mediators will open a new area of novel biomarkers relying on abnormal bone-cartilage communication. 
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Purpose: Skeletogenesis and bone fracture healing involve endochondral ossification, a process during which cartilaginous primordia are gradually replaced by bone tissue. In line with a role for cyclooxygenase-2 (COX-2) in the endochondral ossification process, non-steroidal anti-inflammatory drugs (NSAIDs) were reported to negatively affect bone fracture healing due to impaired osteogenesis. However, a role for COX-2 activity in the chondrogenic phase of endochondral ossification has not been addressed before.
Methods: The role of COX-2 was studied during chondrogenic differentiation of ATDC5 cells and rabbit periosteal explants. BMP-2 was used to increase hypertrophic differentiation and the NSAIDs NS398 and Celecoxib were applied to specifically inhibit COX-2 activity. Chondrogenic outcome was measured by gene-and protein expression analysis, and (immuno) histochemical stainings. For in vivo evidence skeletally immature NZW rabbits were treated with Celecoxib (10mg/kg) for 21 days. Growth plate development was analyzed by histochemistry. Results: Our data reveal essential cross-talk between COX-2 and BMP-2 during chondrocyte hypertrophic differentiation. BMP-2 mediated chondrocyte hypertrophy is associated with increased COX-2 expression and pharmacological inhibition of COX-2 activity decreased BMP-2 induced hypertrophic differentiation in independent chondrogenic models in vitro and ex vivo, while leaving chondrogenesis unaltered. Importantly, systemic inhibition of COX-2 activity in vivo resulted in significantly decreased growth plate thickness, which could be attributed to impaired chondrocyte hypertrophic differentiation.
Conclusions: Our findings demonstrate that COX-2 is an important executing factor of BMP-2-induced chondrocyte hypertrophy in the context of endochondral ossification. These observations provide a novel etiological perspective on the adverse effects of NSAIDs on bone fracture healing and have important implications for the use of NSAIDs during endochondral skeletal development. In addition, our data provides a novel strategy to improve the outcome of cartilage regenerative medicine by decreasing the level of unwanted chondrocyte hypertrophy and ossification. Abstracts / Osteoarthritis and Cartilage 20 (2012) S54-S296 S139
